Press release
Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment
NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled over 50% of patients planned for its Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH). Patients continue to be screened at sites in the U.S. and Israel.\n \n \nThe double-blind, multi-center trial is assessing the safety and potential efficacy of ORMD-0801 in Type 2 diabetes patients with NASH. Efficacy endpoints including percentage change in liver fat content, liver fibrosis, and liver steatosis from baseline will be measured via MRI-PDFF following 12 weeks of dosing. \n\"With more than half of NASH patients having diabetes, ORMD-0801 has the potential to improve outcomes for patients in both conditions. NASH is a disease with a significant unmet medical need, as no drugs are currently approved to treat this condition, which is a leading cause of liver transplants in the U.S. We are excited to build upon our pilot study's results which showed a reduction in liver fat content to demonstrate the potential for ORMD-0801 to help patients living with NASH,\" said Oramed Chief Executive Officer, Nadav Kidron. \nThe global market for drugs to treat NASH is expected to reach $84 billion by 2029. \nAbout NASH\nNon-alcoholic steatohepatitis (NASH) is a serious, progressive liver disease caused by a buildup of fat in the liver and accompanied by inflammation, liver cell damage, and in some cases, scarring of the liver. Over time, NASH may progress to cirrhosis, liver cancer, liver failure, and even death. Currently, no pharmacotherapy is globally approved for the treatment of NASH, and people with NASH are left with very few management options.\nAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral in...